Admission to Trading

3rd May 2019

Bermele, a Company formed to acquire a target company (or companies) with realisable or developed commercial technologies in the pharmaceutical and biotechnology sector, is pleased to announce that its entire issued ordinary share capital consisting of 200,000,000 Ordinary Shares of 0.1p each….Download the full RNS below

Download News

Back to all News